A massive study involving 256,492 adults suggests GLP-1 medications offer superior protection against death and heart attacks compared to metformin. Presented at the 2026 American Heart Association's Scientific Sessions, the findings focus on patients living with prediabetes.

Advertisement

A 41 percent reduction in all-cause mortality

The most significant finding in the new analysis involves the survival gap between different medication groups. The report says GLP-1 users—including those taking semaglutide, tirzepatide, liraglutide, or dulaglutide—faced a 41 percent lower risk of death from any cause compared to those taking the traditional medication metformin. This mortality gap was much larger than researchers initially anticipated, suggesting the drugs work through mechanisms that go far beyond simple glycemic control.

Beyond survival, these modern medications also showed a superior ability to manage blood sugar. According to the data, patients using GLP-1 receptor agonists were approximately 1.5 times more likely to return their blood sugar levels to normal ranges than those on metformin. Additionally, the study found that GLP-1 users exhibited a 31 percent lower risk of progressing to full-blown Type 2 diabetes.

15 percent fewer heart attacks and 20 percent fewer strokes

Cardiovascular health metrics heavily favored the GLP-1 group across several critical clinical indicators. Users of these medications experienced 15 percent fewer heart attacks and 20 percent fewer strokes than their counterparts using metformin. The data also highlighted a 25 percent reduction in cases of heart failure and an 8 percent lower risk of developing atrial fibrillation.

Lead study author Vinicius de Sousa Barzon , a research fellow at Mayo Clinic in Scottsdale, Arizona, expressed surprise at the breadth of these benefits. Dr. Barzon noted that the protective effects against various cardiovascular events occurred with similar magnitude , reinforcing the idea that these drugs offer comprehensive systemic protection rather than just isolated metabolic improvements.

The 76 percent female majority in TriNetX records

The study utilized electronic health records from the TriNetX global health network to analyze a population with an average age of 52. The participant pool was notably demographic-specific, with women constituting 76 percent of the group, a split that reflects current prescription trends for obesity and metabolic conditions. The analysis specifically targeted adults diagnosed with both prediabetes and obesity, a high-risk category.

This research arrives at a critical time for public health, as nearly 40 percent of U.S. adults currently have prediabetes. With up to 10 percent of those individuals progressing to Type 2 diabetes every year, the ability to intervene during this window is vital. The findings suggest that the period of prediabetes may be a key opportunity for clinicians to utilize GLP-1 medications to prevent long-term cardiovascular damage.

Can observational data prove GLP-1s cause better outcomes?

Despite the striking associations, several critical questions remain regarding the study's methodology and the potential for bias. Because the research was observational rather than a randomized controlled trial, endocrinologist Bradley Neutel, founder of Coastline Endocrinology, warned that confounding variables could influence the results. Neutel pointed out that patients prescribed newer, more expensive GLP-1 medications might differ from those on low-cost metformin in terms of socioeconomic status, lifestyle, or overall health consciousness.

Furthermore,the findings have not yet undergone peer review or formal publication in a scientific journal. This leaves several aspects of the study unverified, including whether the improved outcomes were caused directly by the drugs or were simply correlated with the higher level of healthcare access available to those who can afford them.. Until more rigorous trials are completed, the direct causal link remains an open question.